Boundless Bio announces FDA accepted IND application of BBI-940

Boundless Bio (BOLD) announced that the U.S. Food and Drug Administration, FDA, has accepted its Investigational New Drug, IND, application for its novel Kinesin oral degrader program, BBI-940. The acceptance of the BBI-940 IND enables Boundless to advance the program into a first-in-human clinical trial for patients with metastatic breast cancer, KOMODO-1, which is expected to initiate in the first half of 2026. The Company expects to deliver initial proof-of-concept clinical data within its cash runway timeline. Based on the revised operating plan, the Company’s streamlined operations will extend its operating runway into the second half of 2028, through the anticipated initial clinical proof of concept readout for BBI-940.